Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease

NCT01049984 is registered in ClinicalTrials.gov with Teva Neuroscience, Inc. as lead sponsor.

NCT NCT01049984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01049984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of Rasagiline as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson's Disease
Lead sponsor
Teva Neuroscience, Inc.
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2009
Completion date
October 31, 2012
Enrollment
328 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease